Stock listing
Frankfurt:5VB Nykode Therapeutics ASA Aktie
German listing (Frankfurt) of Nykode Therapeutics ASA · home listing Oslo:NYKD
Follow Nykode Therapeutics ASA into a list and get an email when it puts out news.
Share price · FWB:5VB
€0.211 EUR -0.009 (-3.9%)
Close on Nov 20, 2026
- Day range
- €0.211 – €0.211 EURNov 20, 2026
- Market cap
- €82.42M EURAt the close on Nov 20, 2026 · price × 391.5M shares outstanding
- 52-week range
- €0.139 – €0.444 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €251 EURMedian day 0 shares · 50 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Oslo:NYKD · Home | 2.665 NOK | -0.075 (-2.7%) | 1,153,599 | 2.75 | 2.755 | 2.62 | 2.74 | Close on Nov 20, 2026 |
| OTC:VACBF | $0.297 USD | 0.000 (0.0%) | — | $0.297 | $0.297 | $0.297 | $0.297 | Close on Nov 6, 2026 |
| Stuttgart:5VB | €0.233 EUR | -0.007 (-2.9%) | — | €0.238 | €0.247 | €0.215 | €0.240 | Close on Nov 20, 2026 |
| Frankfurt:5VB | €0.211 EUR | -0.009 (-3.9%) | — | €0.211 | €0.211 | €0.211 | €0.219 | Close on Nov 20, 2026 |
| Munich:5VB | €0.322 EUR | -0.002 (-0.5%) | — | €0.322 | €0.322 | €0.322 | €0.323 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:5VB · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.242 | -0.011 | -4.3% | €0.242 | €0.242 | €0.242 | 0 | |
| €0.253 | +0.006 | +2.4% | €0.253 | €0.253 | €0.253 | 0 | |
| €0.247 | +0.008 | +3.3% | €0.247 | €0.247 | €0.247 | 0 | |
| €0.239 | -0.111 | -31.7% | €0.239 | €0.239 | €0.239 | 5,600 | |
| €0.350 | +0.100 | +40.0% | €0.350 | €0.350 | €0.350 | 2,800 | |
| €0.250 | -0.005 | -2.0% | €0.250 | €0.250 | €0.250 | 0 | |
| €0.255 | -0.007 | -2.7% | €0.255 | €0.255 | €0.255 | 0 | |
| €0.262 | 0.000 | 0.0% | €0.262 | €0.262 | €0.262 | 0 | |
| €0.262 | +0.001 | +0.4% | €0.262 | €0.262 | €0.262 | 0 | |
| €0.261 | -0.007 | -2.6% | €0.261 | €0.261 | €0.261 | 0 | |
| €0.268 | -0.007 | -2.5% | €0.268 | €0.268 | €0.268 | 0 | |
| €0.275 | +0.014 | +5.4% | €0.275 | €0.275 | €0.275 | 0 | |
| €0.261 | -0.001 | -0.4% | €0.261 | €0.261 | €0.261 | 0 | |
| €0.262 | +0.006 | +2.3% | €0.262 | €0.262 | €0.262 | 0 | |
| €0.256 | +0.001 | +0.4% | €0.256 | €0.256 | €0.256 | 0 | |
| €0.255 | -0.005 | -1.9% | €0.255 | €0.255 | €0.255 | 0 | |
| €0.260 | 0.000 | 0.0% | €0.260 | €0.260 | €0.260 | 0 | |
| €0.260 | -0.018 | -6.5% | €0.260 | €0.260 | €0.260 | 0 | |
| €0.278 | -0.003 | -1.1% | €0.278 | €0.278 | €0.278 | 0 | |
| €0.281 | +0.006 | +2.2% | €0.281 | €0.281 | €0.281 | 0 | |
| €0.275 | -0.012 | -4.2% | €0.275 | €0.275 | €0.275 | 0 | |
| €0.287 | -0.002 | -0.7% | €0.287 | €0.287 | €0.287 | 0 | |
| €0.289 | -0.005 | -1.7% | €0.289 | €0.289 | €0.289 | 0 | |
| €0.294 | +0.015 | +5.4% | €0.294 | €0.294 | €0.294 | 0 | |
| €0.279 | +0.001 | +0.4% | €0.279 | €0.279 | €0.279 | 0 | |
| €0.278 | -0.007 | -2.5% | €0.278 | €0.278 | €0.278 | 0 | |
| €0.285 | -0.036 | -11.2% | €0.285 | €0.285 | €0.285 | 0 | |
| €0.321 | +0.031 | +10.7% | €0.292 | €0.323 | €0.287 | 24,118 | |
| €0.290 | -0.006 | -2.0% | €0.290 | €0.290 | €0.290 | 0 | |
| €0.296 | -0.016 | -5.1% | €0.318 | €0.320 | €0.295 | 4,000 | |
| €0.312 | -0.013 | -4.0% | €0.312 | €0.312 | €0.312 | 0 | |
| €0.325 | -0.006 | -1.8% | €0.325 | €0.325 | €0.325 | 0 | |
| €0.331 | -0.001 | -0.3% | €0.331 | €0.331 | €0.331 | 0 | |
| €0.332 | +0.001 | +0.3% | €0.332 | €0.332 | €0.332 | 0 | |
| €0.331 | -0.001 | -0.3% | €0.331 | €0.331 | €0.331 | 0 | |
| €0.332 | +0.008 | +2.5% | €0.332 | €0.332 | €0.332 | 0 | |
| €0.324 | +0.008 | +2.5% | €0.324 | €0.324 | €0.324 | 0 | |
| €0.316 | +0.003 | +1.0% | €0.316 | €0.316 | €0.316 | 0 | |
| €0.313 | -0.015 | -4.6% | €0.313 | €0.313 | €0.313 | 0 | |
| €0.328 | -0.044 | -11.8% | €0.328 | €0.328 | €0.328 | 0 | |
| €0.372 | -0.048 | -11.4% | €0.372 | €0.372 | €0.372 | 0 | |
| €0.420 | +0.090 | +27.3% | €0.350 | €0.426 | €0.349 | 1,000 | |
| €0.330 | -0.001 | -0.3% | €0.330 | €0.330 | €0.330 | 0 | |
| €0.331 | -0.006 | -1.8% | €0.331 | €0.331 | €0.331 | 0 | |
| €0.337 | +0.002 | +0.6% | €0.337 | €0.337 | €0.337 | 0 | |
| €0.335 | -0.005 | -1.5% | €0.335 | €0.335 | €0.335 | 0 | |
| €0.340 | +0.003 | +0.9% | €0.340 | €0.340 | €0.340 | 0 | |
| €0.337 | -0.017 | -4.8% | €0.337 | €0.337 | €0.337 | 0 | |
| €0.354 | +0.001 | +0.3% | €0.354 | €0.354 | €0.354 | 0 | |
| €0.353 | -0.032 | -8.3% | €0.353 | €0.353 | €0.353 | 0 | |
| €0.385 | +0.006 | +1.6% | €0.385 | €0.385 | €0.385 | 0 | |
| €0.379 | -0.062 | -14.1% | €0.379 | €0.379 | €0.379 | 0 | |
| €0.441 | +0.061 | +16.1% | €0.387 | €0.442 | €0.383 | 2,000 | |
| €0.380 | +0.006 | +1.6% | €0.380 | €0.380 | €0.380 | 0 | |
| €0.374 | -0.065 | -14.8% | €0.374 | €0.374 | €0.374 | 0 | |
| €0.439 | -0.005 | -1.1% | €0.403 | €0.442 | €0.401 | 4,000 | |
| €0.444 | +0.013 | +3.0% | €0.444 | €0.444 | €0.444 | 0 |
- Ticker
- Frankfurt:5VB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Aug 20, 2026
Nykode Therapeutics Receives New U.S. Patent Strengthening Intellectual Property Protection for its fully individualized VB10.NEO cancer vaccine program
Latest earnings call · Aug 26, 2026
Nykode Therapeutics (Oslo:NYKD) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Sep 16, 2026
H.C. Wainwright 28th Annual Global Investment Conference 2026
Conference · 27 slides
Latest news
Nykode Therapeutics Receives New U.S. Patent Strengthening Intellectual Property Protection for its fully individualized VB10.NEO cancer vaccine program
Aug 20, 2026
Closed €0.444 (+3.0%) on Aug 20, 2026
Q1 2026 Financial Results Q1 2026 Webcast presentation
May 27, 2026
Closed €0.271 (+3.0%) on May 27, 2026
Q1 2026 Financial Results Nykode Q1 2026 Report
May 27, 2026
Closed €0.271 (+3.0%) on May 27, 2026
Nykode Therapeutics reports Q1 2026 Financial Results
May 27, 2026
Closed €0.271 (+3.0%) on May 27, 2026
Nykode Therapeutics - Quarterly Report Q1 2026
May 27, 2026
Closed €0.271 (+3.0%) on May 27, 2026
Invitation to Q1 2026 Financial Results Presentation
May 18, 2026
Closed €0.243 (-4.0%) on May 18, 2026
Q4 2025 Financial Results Q4 2025 Webcast presentation
Feb 27, 2026
Closed €0.242 (-2.8%) on Feb 27, 2026
Nykode Therapeutics reports Q4 2025 Financial Results
Feb 25, 2026
Closed €0.279 (+1.5%) on Feb 25, 2026
Q4 2025 Financial Results Nykode Q4 2025 Report
Feb 25, 2026
Closed €0.279 (+1.5%) on Feb 25, 2026
Nykode Therapeutics - Quarterly Report Q4 2025
Feb 25, 2026
Closed €0.279 (+1.5%) on Feb 25, 2026
Nykode Therapeutics ASA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 12 in the last 12 months · 12 in all · newest Aug 20, 2026 · oldest 2026
- Calls
- 11 calls with a replay · 11 with a transcript · latest Aug 26, 2026
- Decks
- 54 decks · latest Sep 16, 2026
Where Nykode Therapeutics ASA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Oslo:NYKD · Home listing | Oslo | Norway | NOK |
| Aquis:NYKDO | Aquis | United Kingdom | NOK |
| OTC:VACBF | OTC | United States | USD |
| gettex:5VB | gettex | Germany | EUR |
| Stockholm:NYKDO | Stockholm | Sweden | NOK |
| Lang & Schwarz:A2PZ5J | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2PZ5J | LS Exchange | Germany | EUR |
| Stuttgart:5VB | Stuttgart | Germany | EUR |
| Turquoise:NYKDO | Turquoise | United Kingdom | NOK |
| Aquis:NYKDO | Aquis | United Kingdom | NOK |
| Dusseldorf:5VB | Dusseldorf | Germany | EUR |
| Frankfurt:5VB · This page | Frankfurt | Germany | EUR |
| Munich:5VB | Munich | Germany | EUR |
Valuation
Price/book 1.3× against a median of 3.0×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 606.8M NOK
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Nykode Therapeutics ASA · OSL:NYKD | US$107.0M | US$62.24M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| OnKure Therapeutics, Inc. · NASDAQ:OKUR | US$109.4M | −US$53.16M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 1.17 |
| Spruce Biosciences, Inc. · NASDAQ:SPRB | US$109.2M | US$41.00M | n/a | n/a | n/a | 1.6× | n/a | 0.3× | 1.73 |
| NIBEC Co., Ltd. · KRX:138610 | US$108.7M | US$92.50M | n/a | 5.5× | 118× | 3.0× | −0.1% | 0.0× | n/a |
| Jyong Biotech Ltd. · NASDAQ:MENS | US$107.6M | US$125.0M | n/a | n/a | n/a | n/a | n/a | n/a | 1.74 |
| JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126 | US$105.3M | US$84.72M | n/a | 2.0× | n/a | 1.6× | −195.8% | 0.6× | n/a |
| Genelux Corporation · NASDAQ:GNLX | US$104.3M | US$93.85M | n/a | 11,732× | n/a | 11.4× | n/a | 0.0× | 1.52 |
| Cardiol Therapeutics Inc. Class A · TSX:CRDL | US$103.4M | US$83.06M | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.45 |
| Heidelberg Pharma AG · XETR:HPHA | US$103.2M | US$81.75M | n/a | 8.0× | n/a | n/a | −320.9% | n/a | n/a |
| Foghorn Therapeutics Inc. · NASDAQ:FHTX | US$103.1M | −US$9.22M | 10.9× | −0.1× | −2.5× | n/a | 8.4% | n/a | 1.57 |
| Vivani Medical, Inc. · NASDAQ:VANI | US$102.8M | US$88.24M | n/a | n/a | n/a | 7.8× | n/a | 0.0× | 0.93 |
| Median of the others | US$104.8M | US$83.89M | 10.9× | 5.5× | 57.5× | 3.0× | −97.9% | 0.0× | 1.52 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 7.50 NOK · Analysts' mean
- EPS, year to Dec 2026
- -0.75 · 2 analysts
- Revenue, year to Dec 2026
- 928K · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Engsig | Chief Executive Officer |
| Harald Gurvin | Chief Financial Officer |
| Louise Stubbe | Chief Legal Officer |
| Agnete B. Fredriksen | Chief Scientific Officer & Business Development |
| Jakob Helding Rasmussen | Chief Technology Officer |
Board
| Director | Role |
|---|---|
| Barbara Krebs-Pohl | Chair of the Board |
| Christian Åbyholm | Board Member |
| John Beadle | Board Member |
| Susanne Stuffers | Board Member |
| Trygve Lauvdal | Board Member |
Events
- Next results
- Nov 23, 2026 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Nykode Therapeutics (Oslo:NYKD) Q2 2026 Earnings Call | Wed, Aug 26, 2026 · 3:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q1 2026 Earnings Call | Wed, May 27, 2026 · 9:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q4 2025 Earnings Call | Wed, Feb 25, 2026 · 7:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q3 2025 Earnings Call | Mon, Nov 24, 2025 · 4:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q2 2025 Earnings Call | Wed, Aug 27, 2025 · 4:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q1 2025 Earnings Call | Wed, May 28, 2025 · 4:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 7:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q3 2024 Earnings Call | Wed, Nov 27, 2024 · 2:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q2 2024 Earnings Call | Wed, Aug 21, 2024 · 2:00 AM ET | Replay |
| Nykode Therapeutics (Oslo:NYKD) Q4 2022 Earnings Call | Tue, Feb 28, 2023 · 10:00 AM ET | Replay |
All 11 calls
| Call | When | Status |
|---|---|---|
| Nykode Therapeutics (Oslo:NYKD) Q3 2022 Earnings Call | Wed, Nov 23, 2022 · 9:58 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2026 | Aug 26, 2026 · Before open | −0.9% |
| Q1 2026 | May 27, 2026 · Before open | −6.4% |
| Q4 2025 | Feb 25, 2026 · Before open | −9.7% |
| Q3 2025 | Nov 23, 2025 · After close | +3.6% |
| Q2 2025 | Aug 27, 2025 · Before open | −9.8% |
| Q1 2025 | May 27, 2025 · After close | −1.1% |
| Q4 2024 | Feb 26, 2025 · Before open | +1.4% |
| Q3 2024 | Nov 26, 2024 · After close | +5.0% |
| Q2 2024 | Aug 21, 2024 · Before open | −47.0% |
| Q1 2024 | May 14, 2024 · Before open | +2.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Feb 28, 2024 · Before open | −5.8% |
| Q3 2023 | Nov 15, 2023 · After close | +1.1% |
| Q2 2023 | Aug 22, 2023 · After close | −0.2% |
| Q1 2023 | May 12, 2023 · Before open | +5.7% |
| Q4 2022 | Feb 28, 2023 · Before open | −2.5% |
| Q3 2022 | Nov 23, 2022 · Before open | −1.8% |
| Q2 2022 | Aug 24, 2022 · Before open | +0.5% |
| Q1 2022 | May 16, 2022 · Before open | −4.4% |
| Q3 2021 | Nov 17, 2021 · Before open | −0.9% |
| Quarter to Jun 30, 2021 | Aug 26, 2021 · Before open | −4.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H.C. Wainwright 28th Annual Global Investment Conference 2026 | Conference | 27 slides | Sep 16, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 28 slides | Aug 26, 2026 |
| Investor Presentation (August 2026) | Investor deck | 73 slides | August 2026 |
| Q1 2026 Earnings Presentation | Earnings | 27 slides | May 27, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 67 slides | May 27, 2026 |
| DNB Carnegie's Nordic Healthcare Conference 2026 | Conference | 32 slides | Mar 10, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 31 slides | Feb 25, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 27 slides | Feb 25, 2026 |
| Investor Presentation (January 2026) | Investor deck | 93 slides | January 2026 |
| Investor Presentation (December 2025) | Investor deck | 93 slides | December 2025 |
All 54 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 8.68M | 12.9M | 7.17M | 34.0M | 215.0M | 12.4M | 12.0M | 9.76M | 24.0K |
| Gross profit | 8.68M | 12.9M | 7.17M | 34.0M | 215.0M | 12.4M | 12.0M | 9.76M | ||
| Research and development | 13.4M | 14.7M | 29.4M | 26.8M | 16.3M | 10.6M | 60.8M | |||
| Selling, general and administrative | 13.6M | 4.34M | 6.28M | 8.89M | 9.28M | 8.56M | 6.08M | 2.32M | 1.60M | 841.5K |
| Operating income | -28.6M | -48.3M | -58.1M | -53.2M | -10.8M | 178.3M | -122.4M | -65.8M | -34.0M | -1.62M |
| Depreciation and amortization | 2.04M | 743.0K | 629.0K | 1.81M | 734.0K | 304.0K | 1.40M | 58.0K | 58.0K | 8.31K |
| EBITDA | -26.5M | -47.6M | -57.5M | -51.3M | -10.0M | 178.6M | -121.0M | -65.8M | -33.9M | -1.61M |
| Interest expense | 125.0K | 6.18M | 4.68M | 241.0K | 130.0K | 46.0K | 24.0K | 9.20K | 0 | 0 |
| Income before tax | -17.7M | -45.5M | -44.1M | -51.0M | -11.1M | 180.9M | -120.2M | -63.8M | -31.4M | -1.60M |
| Income tax | -6.69M | -8.93M | -8.24M | -1.70M | 31.1M | |||||
| Net income | -12.2M | -38.8M | -35.2M | -42.7M | -9.41M | 149.8M | -120.2M | -63.8M | -31.4M | -1.60M |
| Earnings per share, basic | -0.04 | -0.12 | -0.12 | -0.14 | -0.04 | 0.51 | -0.41 | -0.26 | -0.13 | -0.03 |
| Earnings per share, diluted | -0.12 | -0.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 60.3M | 115.4M | 162.6M | 205.8M | 215.8M | 183.4M | 89.2M | 3.63M | 3.80M | 2.87M |
| Short-term investments | 0 | 12.2M | 24.9M | 190.3M | 143.6M | 206.4M | ||||
| Receivables | 386.0K | 0 | 3.81M | 25.3M | 19.7M | 8.78K | 8.31M | 6.96M | ||
| Current assets | 61.9M | 117.1M | 165.7M | 211.9M | 255.9M | 229.0M | 291.2M | 152.9M | 214.0M | 24.9M |
| Property, plant and equipment | 5.68M | 3.74M | 4.41M | 9.53M | 9.16M | 408.0K | 173.0K | 110.0K | 89.2K | 9.60K |
| Total assets | 100.0M | 153.5M | 208.2M | 221.5M | 265.6M | 230.0M | 293.1M | 153.3M | 214.5M | 24.9M |
| Accounts payable | 4.07M | 3.68M | 7.06M | 2.31M | 2.75M | 1.61M | 13.4M | 5.52M | 6.08M | |
| Current liabilities | 6.19M | 9.10M | 20.6M | 39.0M | 31.4M | 13.2M | 37.9M | 13.3M | 10.9M | 1.74M |
| Total debt | 3.44M | 5.73M | 5.51M | 7.17M | 284.0K | 790.1K | ||||
| Total liabilities | 8.42M | 17.3M | 36.9M | 64.5M | 71.5M | 51.2M | 50.5M | 13.3M | 10.9M | 1.74M |
| Shareholders' equity | 91.5M | 136.2M | 171.3M | 157.0M | 194.1M | 178.8M | 242.6M | 140.1M | 203.5M | 23.2M |
| Shares outstanding | 326.5M | 323.5M | 300.5M | 301.5M | 264.3M | 292.6M | 292.8M | 242.4M | 241.8M | 55.8M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -29.5M | -51.2M | -96.6M | -20.7M | 1.16M | 180.3M | -92.1M | -62.8M | -62.8M | -1.60M |
| Capital spending | -38.0K | -71.0K | -1.90M | -2.67M | -871.0K | -99.0K | -667.2K | -79.0K | -79.0K | -6.43K |
| Free cash flow | -29.5M | -51.3M | -98.5M | -23.4M | 284.0K | 180.2M | -92.7M | -62.9M | -62.9M | -1.61M |
| Cash from investing | 3.52M | 6.93M | 7.04M | 11.1M | 10.8M | -6.02M | -79.5M | -79.0K | -79.0K | 28.9K |
| Cash from financing | -33.6M | -1.40M | 44.6M | 360.0K | 20.4M | -290.0K | 227.1M | 337.0K | 337.0K | 2.35M |
| Dividends paid | -32.3M | |||||||||
| Share buybacks | 0 | 45.7M | 1.80M | 21.2M | 0 | 26.0M | 37.5K | 23.3M | 2.37M | |
| Change in cash | -55.1M | -45.7M | -45.0M | -9.85M | 32.4M | 173.7M | -55.3M | 144.5M | -62.5M | 782.8K |
Cap table
Built by 6ix from Nykode Therapeutics ASA’s releases
- Common shares
- 391,546,444
- Fully diluted
- 391,546,444
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 391,546,444 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 391,546,444 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Agnete B. Fredriksen | Chief Scientific Officer & Business Development · Since at least Aug 20, 2026 |
| Barbara Krebs-Pohl | Chair of the Board · Since at least May 27, 2026 |
| Christian Åbyholm | Board Member · Since at least May 27, 2026 |
| Harald Gurvin | Chief Financial Officer · Since at least May 27, 2026 |
| Jakob Helding Rasmussen | Chief Technology Officer · Since at least Nov 5, 2026 |
| John Beadle | Board Member · Since at least May 27, 2026 |
| Louise Stubbe | Chief Legal Officer · Since at least Nov 5, 2026 |
| Michael Engsig | Chief Executive Officer · Since at least Aug 20, 2026 |
| Susanne Stuffers | Board Member · Since at least May 27, 2026 |
| Trygve Lauvdal | Board Member · Since at least May 27, 2026 |
Log in to ask 6ix AI your own questions about Nykode Therapeutics ASA.